Instrument Inactif

Autres langues US Rare Earth Minerals Inc Other OTC

Actions

US9034101082

Recherche biotechnologique et médicale

Cours en clôture Other OTC
- ^USD	-

14/08	Bioxytran, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
11/08	Bioxytran publie des observations cliniques sur le premier patient atteint de polyradiculonévrite inflammatoire démyélinisante chronique traité par PLICID	CI

Autres langues

14/08	Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
11/08	Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence
11/08	Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID
04/08	Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
04/08	Bioxytran, Inc. and University Of Minnesota Department Of Chemistry Execute Second Sponsored Research Agreement To Advance ASI-Powered Carbohydrate Drug Design Platform
30/07	US officials pressed China on rare earths, farm goods commitments, Bessent says
29/07	Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
29/07	Bioxytran Announces Publication of Corporate Research Report Discussing Prolectin-M Phase 2 Results, Planned 408-Patient Registrational Trial, Bxt-25 Oxygen-Therapeutic Platform, and A-Suqar Commercial Distribution Agreement
16/07	Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
29/05	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
15/05	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/04	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
15/04	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt
20/03	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
18/03	Bioxytran, Inc. announced that it has received $1.158942 million in funding
04/03	Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
04/03	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M
02/03	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19
23/02	Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus
17/02	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
17/02	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement
11/02	Bioxytran reports positive phase 2 results demonstrating rapid viral clearance with Prolectin-Mbioxytran
11/02	Bioxytran, Inc. Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with Prolectin-Mbioxytran
11/02	Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
02/02	Bioxytran, Inc. and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics